Literature DB >> 9854681

Outcome of pregnancy after radioactive iodine treatment for well differentiated thyroid carcinomas.

J D Lin1, H S Wang, H F Weng, P F Kao.   

Abstract

This study sought to determine the outcome of pregnancy in female patients with differentiated thyroid carcinoma who became pregnant after radioactive iodide treatment. A total of 779 female thyroid cancer patients were treated at Chang Gung Medical Center in Linkou between January 1977 and December 1995. The medical records of these patients were reviewed retrospectively. Thirty-seven of these patients had well differentiated thyroid carcinoma receiving 131I treatment and conceived at a mean age of 27.97 +/- 3.49 year-old. A total of 58 pregnancy episodes were recorded during this study period. Among these 37 patients, 3 episodes of artificial abortion, 8 episodes of spontaneous abortion and 2 threatened abortions were observed. These patients delivered a total of 47 babies including 3 premature babies. Seven of these patients conceived within 6 months after the last administration of 131I, including 2 cases within 1 month, 4 cases within 4 months, and 1 patient within 5 months. Of these 7 patients, only one patient who conceived within 6 months after the last administration of 131I (14.3%) had a spontaneous abortion. The present results suggest that previous administration of 131I in female patients with well differentiated thyroid cancer does not result in demonstrable adverse effects in subsequent pregnancies. However, further studies involving long-term follow-up of children delivered by mothers who became pregnant within 6 months after the last administration of 131I is needed to further elucidate the possible chronic effects and sequelae of 131I therapy on subsequent pregnancies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9854681     DOI: 10.1007/bf03350795

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  15 in total

1.  The accumulation of radioactive iodine by human fetal thyroids.

Authors:  R E HODGES; T C EVANS; J T BRADBURY; W C KEETTEL
Journal:  J Clin Endocrinol Metab       Date:  1955-06       Impact factor: 5.958

2.  Outcome of pregnancy following treatment of well-differentiated thyroid cancer with 131iodine.

Authors:  K K Balan; M Critchley
Journal:  Br J Obstet Gynaecol       Date:  1992-12

3.  Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients.

Authors:  M Schlumberger; F De Vathaire; C Ceccarelli; M J Delisle; C Francese; J E Couette; A Pinchera; C Parmentier
Journal:  J Nucl Med       Date:  1996-04       Impact factor: 10.057

4.  Management of hyperthyroidism in children and adolescents.

Authors:  J I Hamburger
Journal:  J Clin Endocrinol Metab       Date:  1985-05       Impact factor: 5.958

Review 5.  The indications for ablating normal thyroid tissue with 131I in differentiated thyroid cancer.

Authors:  A W Goolden
Journal:  Clin Endocrinol (Oxf)       Date:  1985-07       Impact factor: 3.478

6.  Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer: potential risks and recommendations.

Authors:  D Casara; D Rubello; G Saladini; A Piotto; M R Pelizzo; M E Girelli; B Busnardo
Journal:  Eur J Nucl Med       Date:  1993-03

7.  The long-term hazards of the treatment of thyroid cancer with radioiodine.

Authors:  C J Edmonds; T Smith
Journal:  Br J Radiol       Date:  1986-01       Impact factor: 3.039

8.  An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan.

Authors:  W H Beierwaltes; R Rabbani; C Dmuchowski; R V Lloyd; P Eyre; S Mallette
Journal:  J Nucl Med       Date:  1984-12       Impact factor: 10.057

9.  Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases.

Authors:  N A Samaan; Y K Maheshwari; S Nader; C S Hill; P N Schultz; T P Haynie; R C Hickey; R L Clark; H Goepfert; M L Ibanez; C E Litton
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

10.  Radioiodine treatment of Graves' disease. An assessment of its potential risks.

Authors:  G D Graham; K D Burman
Journal:  Ann Intern Med       Date:  1986-12       Impact factor: 25.391

View more
  6 in total

Review 1.  Risk of Adverse Pregnancy Outcomes in Young Women with Thyroid Cancer: A Systematic Review and Meta-Analysis.

Authors:  Shinje Moon; Ka Hee Yi; Young Joo Park
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

Review 2.  Thyroid nodules and cancer during pregnancy, post-partum and preconception planning: Addressing the uncertainties and challenges.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2019-11-22       Impact factor: 4.690

3.  Risk of Adverse Obstetric Outcomes and the Abnormal Growth of Offspring in Women with a History of Thyroid Cancer.

Authors:  Geum Joon Cho; So-Youn Kim; Hoi Chang Lee; Kyu-Min Lee; Sung Won Han; Min-Jeong Oh; Teresa K Woodruff
Journal:  Thyroid       Date:  2019-05-09       Impact factor: 6.568

4.  Long-Term Quality of Life and Pregnancy Outcomes of Differentiated Thyroid Cancer Survivors Treated by Total Thyroidectomy and I(131) during Adolescence and Young Adulthood.

Authors:  Melanie Metallo; Lelia Groza; Laurent Brunaud; Marc Klein; Georges Weryha; Eva Feigerlova
Journal:  Int J Endocrinol       Date:  2016-02-08       Impact factor: 3.257

5.  Pregnancy Outcome After I-131 Therapy for Patients With Thyroid Cancer: A Nationwide Population-Based Cohort Study.

Authors:  Kuan-Yin Ko; Ruoh-Fang Yen; Cheng-Li Lin; Mei-Fang Cheng; Wen-Sheng Huang; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

6.  Follow-up and evaluation of the pregnancy outcome in women of reproductive age with Graves' disease after 131Iodine treatment.

Authors:  Li-Hua Zhang; Jing-Yan Li; Qi Tian; Shuang Liu; Hong Zhang; Sheng Liu; Jiu-Gen Liang; Xian-Ping Lu; Ning-Yi Jiang
Journal:  J Radiat Res       Date:  2016-09-12       Impact factor: 2.724

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.